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ASTRACT 
Background: Cachexia is an important extra-pulmonary manifestation of chronic obstructive 
pulmonary disease (COPD) presenting as unintentional weight loss and altered body 
composition. Previous studies have focused on the relative importance of body composition 
compared to body mass, rather than the relative importance of dynamic compared to static 
measures. We aimed to determine the prevalence of cachexia and pre-cachexia phenotypes in 
COPD, and examine the associations between cachexia and its component features with all-
cause mortality. 
Methods: We enrolled 1755 consecutive outpatients with stable COPD from two London 
centres between 2012-2017, stratified according to European Respiratory Society Task Force 
defined cachexia (unintentional weight loss >5% and low fat free mass index (FFMI)), pre-
cachexia (weight loss >5% but preserved FFMI) or no cachexia. The primary outcome was 
all-cause mortality. We calculated hazard ratios (HR) using Cox proportional-hazards 
regression for cachexia classifications (cachexia, pre-cachexia, no cachexia) and component 
features (weight loss, FFMI) and mortality, adjusting for age, sex, BMI, and disease–specific 
prognostic markers. 
Results: The prevalence of cachexia was 4.6% (95% CI 3.6-5.6) and pre-cachexia 1.6% 
(95% CI 1.0-2.2). Prevalence was similar across sexes but increased with worsening GOLD 
spirometric stage and MRC dyspnoea score (all p <0.001). There were 313 (17.8%) deaths 
over a median (IQR) follow-up duration 1089 (547-1704) days. Both cachexia (HR 1.98 
[95% CI 1.31-2.99], p=0.002) and pre-cachexia (2.79 [95% CI 1.48-5.29], p=0.001) were 
associated with increased mortality. In multivariable analysis, the unintentional weight loss 
feature of cachexia was independently associated with mortality (HR 2.16 [95% CI 1.31-
3.08], p<0.001), whereas low FFMI was not (HR 0.88 [95% CI 0.64-1.20], p=0.402). 
Sensitivity analyses using BMI-, age-, gender-specific low FFMI values found consistent 
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findings. 
Conclusions: Despite the low prevalence of cachexia and pre-cachexia, both confer increased 
mortality risk in COPD, driven by the unintentional weight loss component. Our data suggest 
low FFMI without concurrent weight loss may not confer the poor prognosis as previously 
reported for this group. Weight loss should be regularly monitored in practice and may 
represent an important target in COPD management. We propose the incorporation of weight 
monitoring into national and international COPD guidance.
5 
 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a major cause of global morbidity and 
mortality [1]. Extra-pulmonary manifestations of COPD, such as altered body composition, 
have long been recognized [2] and represent remediable aspects of the disease [3-6] that 
impact on prognosis, reflected by their inclusion within the BODE (body mass index (BMI), 
airflow obstruction, dyspnea, and exercise capacity) prognosis index [7]. 
Cachexia is a complex syndrome that encompasses multiple manifestations of COPD. The 
prominent and dynamic feature of cachexia is unintentional weight loss, driven by a variable 
combination of reduced food intake and metabolic disturbance [8, 9]. The multi-faceted 
nature of cachexia has led to difficulties defining it for study. A consensus definition from the 
Cachexia Consensus Working Group requires the presence of ≥5% weight loss in the 
previous year, or a BMI <20kg/m2, plus ≥3 of 5 markers of metabolic disturbance (decreased 
muscle strength, fatigue, anorexia, low fat-free mas index (FFMI), or abnormal biochemistry) 
to diagnose cachexia [8]. Similarly, diagnosis of a pre-cachexia state defined by the European 
Society of Clinical Nutrition and Metabolism (ESPEN) Special Interest Group on cachexia-
anorexia, requires assessment of weight loss (≤5% in the previous six months), plus markers 
of anorexia and metabolic disturbance [9, 10]. Whilst these detailed assessments help to 
delineate cachexia from other nutritional disorders, they are difficult to apply in large 
epidemiological studies. Indeed, to our knowledge, the Cachexia Consensus Working Group 
definition has not been applied to a COPD cohort in the decade since its publication [8]. 
The European Respiratory Society (ERS) Task Force on nutritional assessment and therapy in 
COPD recently provided expert-derived pragmatic definitions for different metabolic 
phenotypes, using practical assessment modalities that can be more readily applied in practice 
[11]. The Task Force focused on the presenting features of cachexia, rather than the 
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underlying pathophysiology, and defined cachexia as “unintentional weight loss >5% in six 
months and fat free mass index (FFMI) <17kg/m2 in males and <15kg/m2 in females”[11]. 
The FFMI cutoffs relate to the 10th centile of the overall population, which have been 
associated with survival in COPD [5]. The Task Force also defined a pre-cachexia phenotype 
as “unintentional weight loss >5% in six months” but with preserved FFMI to identify an at-
risk group for whom interventions might prevent cachexia or delay its onset [5].  
A prospective validation of these practical definitions is lacking in COPD. Moreover, whilst 
previous studies in COPD have demonstrated the additional prognostic importance of 
baseline body composition compared to BMI alone [3, 5], the relative importance of dynamic 
changes in body composition (e.g. weight loss) compared to static measures has not been 
examined outside of small historical cohorts with very advanced COPD and respiratory 
failure [12]. 
We therefore aimed to determine the prevalence of cachexia and pre-cachexia in patients with 
stable COPD, to characterize the cachexia phenotype, and to examine the associations 
between cachexia and its component features with mortality. We hypothesized that mortality 
risk would be increased in the presence of cachexia as compared with the presence of 
unintentional weight loss or low FFMI alone. 
 
METHODS 
Study design and population 
For this prospective cohort study, a consecutive series of patients attending outpatient 
respiratory, pulmonary rehabilitation and community assessment clinics in northwest London, 
UK, were approached between January 2012 and May 2017. Eligible patients were aged 40 
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years or above, with a ratio of forced expiratory volume in one second (FEV1) to forced vital 
capacity (FVC) of less than 0.7, and a physician diagnosis of COPD consistent with the 
Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines [13]. 
Exclusion criteria were any condition that precluded an incremental exercise test on grounds 
of safety (e.g. unstable cardiac disease) or bioelectrical impedance analysis (BIA) (e.g. an 
implanted pacemaker or defibrillator), a comorbid progressive neuromuscular disorder, a 
current cancer diagnosis, or an exacerbation of COPD within the preceding month that 
required a change in medication. The study was approved by the West London (11/H0707/2) 
and London Camberwell St Giles (11/LO/1780) Research Ethics Committees, London, UK. 
All participants provided informed consent. 
Cachexia classification 
Unintentional weight loss was assessed using current weight (MC-780, Tanita, Illinois, USA) 
and a structured clinical history following BAPEN guidance [14]. Patients were asked if they 
“had lost weight in the last six months?” that was unplanned and if so “how much did you 
weigh six months ago?” from which weight loss was calculated as a percentage [14]. If 
patients reported weight loss but could not provide a prior weight, they were asked if clothes 
and/or jewelry had become loose fitting, taken as significant weight loss [14].  Fat free mass 
(FFM, kg) was estimated using whole-body BIA (Quadscan 4000, Bodystat, Isle of Man, 
UK) and a disease-specific equation [15], expressed as fat free mass index (FFMI = 
FFM/height2 in kgm-2). Using the ERS Task Force on nutritional assessment in COPD 
definitions [11],  patients reporting unintentional weight loss of >5% over the preceding six 
months, and with a FFMI <17kgm-2 for males and <15kgm-2 for females, were classified as 
having cachexia. Patients reporting unintentional weight loss of >5% over the preceding six 
months but with a preserved FFMI were classified as having pre-cachexia. As per usual local 
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practice, those classified as having pre-cachexia or cachexia were provided with an 
information leaflet [16] with dietetic referral based on clinical judgement. Patients with no 
cachexia (no unintentional weight loss) were further classified into those with low or 
preserved FFMI. For a sensitivity analysis, we reclassified low FFMI using BMI-, age- and 
gender-specific cutoffs derived from the UK Biobank [17]. 
Outcomes 
All-cause mortality, our primary outcome, was assessed over a 6-year observation window 
(2012-17). Deaths were recorded up to 29th August 2017 using data retrieved from the UK 
National Health Service “spine”, maintained by the NHS Care Records Service. Age, sex, and 
ethnic origin were recorded from medical records. Other outcomes assessed at study 
enrollment were FEV1 using spirometry, functional exercise capacity using the incremental 
shuttle walk test (ISW)[18], respiratory disability using the Medical Research Council (MRC) 
dyspnea score [19], and health-related quality of life assessed by the COPD Assessment Test 
(CAT) [20]. 
Statistical analysis 
The recruitment target was 1700 participants based on the precision to which cachexia 
prevalence could be estimated: ±2.5% with a large sample normal approximation (nQuery 
Advisor V.6.0), and previous studies that identified modified mortality risk from altered body 
composition parameters. The prevalence of cachexia, with 95% confidence intervals [95% 
CI] calculated using Wilson’s method [21], was determined overall and compared across sex, 
age, GOLD spirometric stage, and MRC dyspnoea score categories using chi-squared for 
trend. Baseline clinical characteristics were compared across groups through one-way 
analysis of variance (ANOVA) or Kruskal-Wallis tests with χ2, independent t-test, Mann-
Whitney U tests for pairwise comparisons. 
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Survival was plotted using Kaplan-Meier curves, and the log-rank test was used to compare 
survival curves according to cachexia classifications (cachexia, pre-cachexia, no cachexia) 
and component features (unintentional weight loss, low FFMI). After censoring and 
proportionality assumptions had been satisfied, associations with mortality were investigated 
using Cox proportional hazards regression models. In univariate separate models, either 
cachexia classifications or component features were entered as independent variables along 
with the covariates age, sex, smoking status, Charlson comorbidity index, exacerbations in 
the previous year, BMI category, FEV1 percent predicted, MRC dyspnoea score, and ISW 
distance as reported predictors of mortality in COPD [22, 23]. After checking for collinearity 
(r<0.75) all variables significantly associated with mortality (p<0.10) were considered in a 
multivariate model. Hazard Ratios (HR) with 95% confidence intervals [CI] were estimated. 
Analyses were performed using SPSS (version 22, IBM, New York) and p values less than 
0.05 were considered significant. 
 
RESULTS 
Patient characteristics 
Of 2250 consecutive patients approached, 1755 (78%) were enrolled. Participants had a mean 
(SD) age of 70 (10) years, FEV1 48.6 (19.5) % predicted, and BMI 27.8 (6.7) kgm-2 (Table 1). 
The most prevalent comorbidities were diabetes, peripheral vascular disease and congestive 
heart failure; present in 10.5%, 6.7% and 4.7% of patients respectively. Overall the 
prevalence of cachexia was 4.6% [95%, CI 3.6-5.6] and the prevalence of pre-cachexia was 
1.6% [95% CI: 1.0-2.2]. The prevalence of cachexia was similar across sexes (male: 4.7% 
[95% CI 3.4-6.0]; female 4.5% [95% CI: 3.1-6.1]) but increased with worsening GOLD 
spirometric stage and MRC dyspnoea score (p for trend <0.001 each). 
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In addition to the defining characteristics of a low body weight and FFMI, patients with 
cachexia presented with significantly reduced FEV1 % predicted and exercise capacity, more 
exacerbations in the previous year (p<0.001 each), and a higher level of respiratory related 
disability (p=0.005) as compared to patients with no cachexia. The groups did not differ 
statistically with respect to sex distribution, age, smoking history, long-term oxygen therapy 
use or health related quality of life (Table 1). Of patients without cachexia or pre-cachexia, 
620/1646 (35.3%) had a low FFMI. Baseline characteristics for this group according to the 
presence of low or preserved fat free mass index are presented in the supplementary material 
(Online Supplement Table S1). 
Mortality 
We recorded 313 deaths (17.8%) over median (IQR) follow-up duration 1089 (547-1704) 
days. All-cause mortality at the end of the first, second and third years of study follow-up was 
5.3%, 10.3% and 15.7% respectively. 
Survival was reduced in groups with baseline cachexia and pre-cachexia as compared to the 
group with no cachexia (both p<0.001). In contrast, no difference in survival was observed 
between groups with baseline cachexia and pre-cachexia (p=0.699) (Figure 1). In univariable 
analyses, both cachexia (Hazard Ratio HR 2.50 [95% CI 1.67-3.75]) and pre-cachexia (HR 
2.82 [95% CI 1.50-5.30]) were associated with mortality, as were advancing age, male sex, 
lower BMI, lower FEV1 % predicted, higher MRC score, and reduced ISW (p<0.001) (Table 
2). In multivariable analysis both cachexia (adjusted HR 1.98 [95% CI 1.31-2.99]) and pre-
cachexia (adjusted HR 2.79 [95% CI 1.48 -5.29] remained independent predictors of 
mortality (Table 2). 
Concerning the component features of cachexia, the survival curve for patients with low 
FFMI but no unintentional weight loss was not significantly different to that of patients with 
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preserved FFMI (p=0.214). Furthermore, in patients with low FFMI, survival was 
significantly reduced in patients with unintentional weight loss compared with those with no 
weight loss (p<0.001) (Figure 2). In univariable analyses considering anthropometric and 
body composition variables, unintentional weight loss (HR 2.58 [95% CI 1.82 to 3.66] and 
low FFMI (HR 1.30 [95% CI 1.04-1.63]) were each associated with mortality, as were 
advancing age, male sex, lower BMI, lower FEV1 % predicted, higher MRC score, Charlson 
score and reduced ISW (p<0.001) (Table 3). In multivariable analysis, unintentional weight 
loss remained a significant predictor of mortality (adjusted HR 2.16 [95% CI 1.51-3.08] 
whereas low FFMI did not (adjusted HR 0.88 [95% CI 0.64-1.20], p=0.402) (Table 3). 
The sensitivity analysis using BMI-, age-, gender-specific low FFMI values, made no 
meaningful difference to the main finding. Low FFMI did not remain in the multivariable 
analysis, whereas unintentional weight loss remained a significant predictor of mortality 
(adjusted HR 2.17 [95% CI 1.50-3.15] after adjusting for age, sex, FEV1 % predicted, 
comorbidity burden, and ISW distance (Online Supplement Table S2). 
 
DISCUSSION 
This large prospective cohort study found a prevalence of 4.6% and 1.6% for cachexia and 
pre-cachexia in outpatients with stable COPD. Patients with these phenotypes had a poorer 
exercise capacity and more severe respiratory disability as compared to those with no 
cachexia, including those with a low FFMI alone. Both cachexia and pre-cachexia were 
associated with increased mortality risk. However, contrary to our hypothesis, low FFMI did 
not add prognostic value to unintentional weight loss alone. Our findings underscore the 
prognostic importance of unintentional weight loss in COPD. 
Low body weight per se has consistently been associated with mortality in COPD, indeed 
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BMI is a component of the BODE index, the best known prognostic index in COPD [22]. 
However, BMI does not take into account abnormalities of body composition; consequently 
the ERS Task Force on nutritional assessment and therapy recommend measures of body 
composition to distinguish between patients with low and normal fat-free mass [11]. This 
recommendation is supported by evidence from two large well-characterized cohort studies 
that demonstrated additional prognostic value of low FFMI for mortality compared with BMI 
alone [3, 5]. 
In line with previous studies, we found reduced FFMI to be associated with increased 
mortality risk when considered in isolation [3, 5]. However, FFMI was no longer an 
independent predictor of mortality when unintentional weight loss and other established 
predictors of poor prognosis were considered in multivariable models. Historical studies have 
focused on the additional prognostic information provided by baseline body composition 
measures, but not dynamic changes in weight or muscle mass. Differences in the composition 
and baseline characteristics of patients may be important, but our data suggest that the 
previously observed effect of low FFMI on survival may be driven by a subgroup with 
unintentional weight loss - a factor not assessed in these cohorts, but studied historically in 
small cohorts of patients with very advanced COPD and respiratory failure [12].  
All definitions of cachexia stress it is a dynamic syndrome characterized by the loss of 
muscle and fat (which manifests as weight loss) [8, 11]. Indirect evidence to support our 
hypothesis is the observation that low FFMI observed in older patients with COPD may be 
long-standing and insidious, and a result of insults earlier in life such as smoking or reduced 
physical activity [24, 25]. Furthermore, cohort studies have shown that continuing decline in 
fat free mass is uncommon in COPD [26] - this was corroborated by our study, with only 
11.5% of patients with low FFMI reporting recent unintentional weight loss. 
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There are potential limitations to our study. First, the prevalence of cachexia in our cohort 
was lower than previously reported [3, 5, 27-30]. This is most likely explained by previous 
studies focusing on cohorts with more advanced COPD, the application of different cachexia 
criteria, and the increase in body size with obesity. We acknowledge that our population 
consisted primarily of stable, Caucasian (93%) outpatients, and our findings need to be 
corroborated in other settings and countries. We hypothesize that the ERS Task Force cut-offs 
for FFMI may over-estimate or under-estimate the prevalence of cachexia in different ethnic 
populations. Cachexia may also be more prevalent in specific settings, such as in care or 
nursing homes or acute hospitals. Second, we assessed unintentional weight loss through 
clinical history as serial measurements of weight were often not recorded in patient care 
records. Multiple measures of weight and body composition would have extended our study 
findings and allowed us to examine the impact of different trajectories on clinical outcome, 
and we recommended longitudinal assessment in future studies. However, we followed a 
consensus-recommended systematic process, and patient-reported weight history is reliable 
[31], and the accepted standard in cancer cachexia [32]. Indeed, viewed from a clinician 
perspective, the fact that patient-reported observations generated powerful data is reassuring. 
Third, it has long been observed that weight loss is associated with a particular COPD 
subtype, namely the “pink puffer” with emphysema [33]. The majority of our stable 
outpatient cohort did not have contemporaneous imaging or full lung function measurements 
to assess the degree of emphysema and so we are unable to exclude this as a confounding 
factor. Finally, unintentional weight loss may have been a manifestation of cancer, which we 
cannot rule out without cause-specific mortality data. However, those with a current cancer 
diagnosis at assessment were excluded from this study.  
Our findings have important and immediate implications for clinical practice and research.  
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Given the prognostic significance of weight loss, we propose that assessing weight change 
should be an essential part of the clinical assessment (both through history and examination) 
of the patient with COPD, and incorporated explicitly into international guidance [13]. 
Although most COPD guidelines acknowledge that malnourished patients may benefit from 
nutritional supplementation, the need for routine nutritional screening is not always 
reinforced, including in GOLD guidelines [13]. Others, for example the latest iteration of the 
United Kingdom NICE guidelines for COPD, recommend annual screening and provision of 
nutritional supplements based on BMI. However, our data demonstrate the value of screening 
directed towards unintentional weight loss and we propose that future iterations of COPD 
guidelines should reflect this. Weight maintenance is a potentially achievable target in COPD. 
For example, recent meta-analyses of nutritional support have shown small but consistent 
effects on weight gain in patients with COPD, particularly in those who are undernourished 
[34, 35]. Moreover in a previous trial of nutritional therapy alone or in combination with 
anabolic steroid treatment, a relatively modest weight gain of >2kg was associated with 
improved survival [27]. Unintentional weight loss should also trigger more detailed clinical 
attention of these patients, who we show are more symptomatic, have more frequent 
exacerbations, and may benefit from additional specialist care to manage symptoms [36]. 
Smoker and ex-smokers are also at risk of neoplasia and clinical examination with 
appropriate investigations may disclose neoplasia in COPD patients with weight loss at a 
point where treatment outcomes are better. 
There is significant interest in understanding the mechanisms underlying low muscle mass in 
patients with COPD [37, 38]. However, our study clearly demonstrates a distinct subgroup 
with unintentional weight loss (defined as cachexia or pre-cachexia by the ERS Task Force). 
Future research should differentiate between phenotypes with unintentional weight loss and 
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those with COPD and constitutionally or long-standing low FFMI. Dynamic measures that 
demonstrate ongoing metabolic dysfunction are required. There are likely to be significant 
mechanistic differences to explain body composition abnormalities in these groups with 
implications for the development of anabolic agents and the identification of patient 
phenotypes that respond best to them [39]. 
In summary, although the prevalence of cachexia and pre-cachexia in outpatients with stable 
COPD is low, these phenotypes are associated with important clinical manifestations 
including poorer exercise tolerance and greater respiratory disability. Unintentional weight 
loss is independently associated with mortality risk in COPD, and regular monitoring of 
weight should be an essential part of the clinical assessment of the patient with COPD. Our 
data suggest low fat free mass index FFMI without concurrent weight loss without weight 
loss may not confer the poor prognosis as previously reported for this group. 
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FIGURE LEGENDS  
 
FIGURE 1. Survival curves for patients with COPD classified according to cachexia phenotypes. 
Both cachexia and pre-cachexia were associated with reduced survival as compared to no cachexia 
(p<0.001). 
 
FIGURE 2. Survival curves for patients with COPD classified by fat-free mass index (FFMI) with or 
without unintentional weight loss. Low FFMI with unintentional weight loss was associated with 
reduced survival as compared to normal FFMI (p<0.001) whereas low FFMI without unintentional 
weight loss was not (p=0.214). 
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TABLE 1. Baseline characteristics of patients with COPD (n=1755) classified according to cachexia, 
pre-cachexia, and no cachexia 
 
 
Data expressed as mean (standard deviation) or median (25th centile, 75th centile) unless stated otherwise.  
*moderate or severe acute exacerbations of COPD, that led to change of medication or required hospitalizations 
 
Abbreviations: BMI: body mass index; FFMI: fat free mass index; FEV1: forced expiratory volume in one 
second; FVC: forced vital capacity; MRC: Medical Research Council; ISW: incremental shuttle walk; CAT: 
COPD Assessment Test.  
 
Cachexia 
(n=81) 
Pre-cachexia 
(n=28) 
No cachexia 
(n=1646) 
p-value 
Male: n (%) 47 (58) 13 (46) 943 (57) 0.332 
Age (years) 70 (10) 72 (11) 70 (9) 0.071 
BMI (kg/m2) 20.0 (3.0) 29.2 (7.2) 28.1 (6.6) <0.001 
BMI category: n (%)    <0.001 
   Low (<18.5) 25 (40) 0 (0) 64 (4)  
   Normal (18.5-24.9) 51 (63) 11 (39) 531 (32)  
   Overweight (25.0-29.9) 5 (6) 6 (21) 512 (31)  
   Obese (≥30) 0 (0) 11 (39) 539 (33)  
Weight(kg) 54.4 (11.4) 77.5 (22.2) 77.1 (20.4) <0.001 
FFMI (kg/m2) 
   Male 
   Female 
14.1 (1.3) 
14.7 (1.2) 
13.3 (0.9) 
17.9 (2.3) 
18.6 (1.8) 
17.2 (2.6) 
17.2 (2.7) 
17.9 (2.6) 
16.1 (2.5) 
<0.001 
<0.001 
<0.001 
Smoking history: n (%) 
   Smoker 
   Ex-smoker 
   Never smoked 
 
24 (30) 
46 (61) 
7 (9) 
 
10 (36) 
18 (64) 
0 (0) 
 
329 (20) 
1197 (73) 
108 (7) 
<0.001 
Number of pack-years 40(17, 58) 38 (21,56) 40 (20, 58) 0.993 
FEV1/FVC 0.41(0.12) 0.49 (0.13) 0.49 (0.13) <0.001 
FEV1(L) 0.88(0.43) 1.14 (0.56) 1.21 (0.56) <0.001 
FEV1 (%predicted) 37(19) 52 (21) 49 (19) <0.001 
GOLD classification(%):  
    Stage I 
    Stage II 
    Stage III 
    Stage IV 
 
 
4 (5) 
11 (14) 
35 (43) 
31 (38) 
 
 
3 (11) 
13 (46) 
7 (25) 
5 (18) 
 
 
116 (7) 
634 (39) 
605 (37) 
291 (18) 
 
 
<0.001 
Oxygen: n (%) 
   Long-term 
   Ambulatory 
 
4 (5) 
5 (6) 
 
0 
0 
 
72 (4) 
71 (4) 
 
0.484 
0.165 
Charlson score 1.5 (1.0) 1.8 (1.3) 1.7 (1.3) 0.241 
MRC dyspnoea score 4 (3,5) 4 (3,5) 
 
3 (2,4) 0.005 
ISW distance (m)  130 (70, 220) 95 (55, 220) 190 (90, 320) <0.001 
CAT score 22 (8) 23 (8) 22 (8) 0.345 
Number of exacerbations* 
in previous 12 months 
3 (2, 4) 3 (1, 6) 
 
2 (1,3) 
<0.001 
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FIGURE 1. Survival curves for patients with COPD classified according to cachexia phenotypes. 
Both cachexia and pre-cachexia were associated with reduced survival as compared to no cachexia 
(p<0.001). 
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TABLE 2. Cox proportional hazard models for all-cause mortality in patients with COPD according 
to cachexia status 
 
 Univariate Multivariate 
Covariate HR 95% CI p value 
adjusted 
HR 
95% CI p value 
Age 1·031 1·018-1·044 <0·001 1.028 1.015-1.042 <0.001 
Sex (male) 1·533 1·213-1·937 <0·001 1.631 1.283-2.074 <0.001 
Smoking (current) 0.845 0.628-1.136 0.264 --- --- 0.451 
FEV1  (% predicted) 0·983 0·977-0·990 <0·001 0.984 0.997-0.991 <0.001 
MRC dyspnoea score 1·285 1·157-1·428 <0·001 --- --- 0.353 
ISW distance 0.996 0.996-0.997 <0·001 0.997 0.996-0.998 <0.001 
Previous exacerbation 1.007 0.974-1.042 0.664 --- --- 0.556 
Charlson score  1.231 1.119-1.353 <0.001 1.157 1.053-1.271 0.002 
BMI  
<18.5 Reference     Reference 
18.5-24.99 0.748 0.476-1.177 0.210 --- --- 0.498 
25-29.99 0.496 0.309-0.795 0.004 --- --- 0.117 
>30 0.546 0.342-0.872 0.011 --- --- 0.218 
No cachexia   Reference      Reference 
Pre-cachexia 2·815 1·496-5·297 0·001 2.794 1.476-5.288 0.002 
Cachexia 2·504 1·674-3·746 <0·001 1.982 1.314-2.989 0.001 
 
Abbreviations: HR: hazard ratio; CI: confidence interval; FEV1: forced expiratory volume in one second; MRC: 
Medical Research Council; ISW: incremental shuttle walk; BMI: body mass index 
 
All variables significantly associated with mortality (p<0.10) in univariate analysis were considered in the 
multivariate model. 
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FIGURE 2. Survival curves for patients with COPD classified by fat-free mass index (FFMI) with or 
without unintentional weight loss. Low FFMI with unintentional weight loss was associated with 
reduced survival as compared to normal FFMI (p<0.001) whereas low FFMI without unintentional 
weight loss was not (p=0.214). 
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Normal FFMI 
 
1054 850 631 403 186 54 0 
Low FFMI without 
weight loss 
 
620 472 274 167 83 28 0 
Low FFMI with weight 
loss 
81 51 34 16 6 1 0 
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TABLE 3. Cox proportional hazard models for all-cause mortality in patients with COPD according 
to cachexia constituents 
 
 
 Univariate Multivariate 
Covariate HR 95% CI p value 
adjusted 
HR 
95% CI p value 
Age 1·031 1·018-1·044 <0·001 1.029 1.015-1.042 <0.001 
Sex (male) 1·533 1·213-1·937 <0·001 1.615 1.272-2.052 <0.001 
Smoking (current) 0.845 0.628-1.136 0.264 --- --- 0.509 
FEV1  (% predicted) 0·983 0·977-0·990 <0·001 0.984 0.978-0.991 <0.001 
MRC dyspnoea 
score 
1·285 1·157-1·428 <0·001 --- --- 0.383 
ISW 0.996 0.996-0.997 <0·001 0.997 0.996-0.998 <0.001 
Previous 
exacerbation 
1.007 0.974-1.042 0.664 --- --- 0.590 
Charlson score 1.231 1.119-1.353 <0.001 1.156 1.053-1.270 0.002 
BMI  
   <18.5 Reference     Reference 
   18.5-24.99 0.748 0.476-1.177 0.210 --- --- 0.548 
   25-29.99 0.496 0.309-0.795 0.004 --- --- 0.113 
   >30 0.546 0.342-0.872 0.011 --- --- 0.196 
>5% unintentional 
weight loss 
2·583 1·823-3·660 <0·001 2.160 1.515-3.079 <0.001 
Low FFMI* 1·300 1·038-1·629 0·022 --- --- 0.402 
 
*Low FFMI defined as FFMI <15/17 kgm-2 females/ males.  
 
Abbreviations: HR: hazard ratio; 95% CI: 95% confidence interval of HR; FEV1: forced expiratory volume in 
one second; MRC: Medical Research Council; ISW: incremental shuttle walk; BMI: body mass index; FFMI: 
fat free mass index. 
 
All variables significantly associated with mortality (p<0.10) in univariate analysis were considered in the 
multivariate model. 
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TABLE S1. Baseline characteristics of patients with COPD without cachexia (n=1646) classified 
according to the presence of low or preserved fat free mass index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data expressed as mean (standard deviation) or median (25th centile, 75th centile) unless stated otherwise.  
*moderate or severe acute exacerbations of COPD, that led to change of medication or required hospitalizations 
Abbreviations: BMI: body mass index; FFMI: fat free mass index; FEV1: forced expiratory volume in one 
second; FVC: forced vital capacity; MRC: Medical Research Council; ISW: incremental shuttle walk; CAT: 
COPD Assessment Test 
 
 
 
Low FFMI 
(n=620) 
Preserved FFMI 
(n=1026) 
p value 
Male: n (%) 369 (60) 574 (56) 0.165 
Age (years) 69 (10) 70 (9) 0.013 
BMI (kg/m2) 22.6 (3.0) 31.4 (6.0) <0.001 
Height (m) 1.66 (0.09) 1.65 (0.10) 0.128 
Weight(kg) 62.5 (11.4) 86.0 (19.5) <0.001 
FFMI (kg/m2) 
   Male 
   Female 
14.77 (1.34) 
15.46 (1.14) 
13.75 (0.88) 
18.6 (2.3) 
19.5 (2.1) 
17.5 (2.1) 
<0.001 
<0.001 
<0.001 
Smoking history (n,%) 
  Smoker 
  Ex-smoker 
   Never smoked 
 
155 (25.2) 
416 (67.5) 
45 (7.3) 
 
174 (17.1) 
781 (76.7) 
63 (6.2) 
<0.001 
Number of pack-years 40 (20,56) 40 (20,60) 0.934 
FEV1/FVC 0.44 (0.13) 0.51 (0.12) <0.001 
FEV1(L) 1.12 (0.55) 1.26 (0.56) <0.001 
FEV1 (%predicted) 45 (20) 52 (18) <0.001 
GOLD stage (n, %) 
    Stage I 
    Stage II 
    Stage III 
    Stage IV 
 
44 (7) 
175 (28) 
238 (38) 
163 (26) 
 
72 (7) 
459 (45) 
367 (36) 
128 (13) 
<0.001 
Oxygen: n (%) 
   Long-term 
   Ambulatory 
 
32 (5) 
34 (6) 
 
40 (4) 
37 (4) 
 
0.263 
0.079 
Charlson score 1.5 (1.0) 1.5 (1.0) 0.523 
MRC dyspnoea score 3 (2,4) 3 (3,4) 0.385 
ISW distance (m)  200 (110, 330) 180 (80, 300) 0.002 
CAT score 22 (8) 21 (8) 0.157 
Number of exacerbations* in 
previous 12 months 
2 (1,3) 2 (1,3) 0.577 
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TABLE S2. Cox proportional hazard models for all-cause mortality in patients with COPD according 
to cachexia constituents using BMI-, age- and gender-specific low fat-free mass index values. 
 
 Univariate Multivariate 
Covariate HR 95% CI p value 
adjusted 
HR 
95% CI p value 
Age 1·031 1·018-1·044 <0·001 1.030 1.016-1.044 <0.001 
Sex (male) 1·533 1·213-1·937 <0·001 1.648 1.288-2.108 <0.001 
Smoking (current) 0.845 0.628-1.136 0.264 --- --- 0.492 
FEV1  (% predicted) 0·983 0·977-0·990 <0·001 0.983 0.977-0.990 <0.001 
MRC dyspnoea 
score 
1·285 1·157-1·428 <0·001 --- --- 0.370 
Previous 
exacerbations 
1.007 0.974-1.042 0.664 --- --- 0.591 
Charlson score  1.231 1.119-1.353 <0.001 1.142 1.037-1.258 0.007 
ISW 0.996 0.996-0.997 <0·001 0.997 0.996-0.998 <0.001 
BMI  
   <18.5 Reference     Reference 
   18.5-24.99 0.748 0.476-1.177 0.210 --- --- 0.623 
   25-29.99 0.496 0.309-0.795 0.004 --- --- 0.173 
   >30 0.546 0.342-0.872 0.011 --- --- 0.315 
>5% unintentional 
weight loss 
2·583 1·823-3·660 <0·001 2.172 1.502-3.140 <0.001 
Low FFMI* 1.211 0.968-1.515 0.094 --- --- 0.903 
 
*Low FFMI defined using as BMI-, age- and gender-specific low FFMI values derived from the UK Biobank 
reference dataset. 
 
Abbreviations: HR: hazard ratio; 95% CI: 95% confidence interval of HR; FEV1: forced expiratory volume in 
one second; MRC: Medical Research Council; ISW: incremental shuttle walk; BMI: body mass index; FFMI: 
fat free mass index. 
 
